156 related articles for article (PubMed ID: 32369961)
61. Value of nonsurgical therapeutic management of stage I bisphosphonate-related osteonecrosis of the jaw.
Bodem JP; Kargus S; Engel M; Hoffmann J; Freudlsperger C
J Craniomaxillofac Surg; 2015 Sep; 43(7):1139-43. PubMed ID: 26116306
[TBL] [Abstract][Full Text] [Related]
62. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
[TBL] [Abstract][Full Text] [Related]
63. Investigation of Sustained BMP Delivery in the Prevention of Medication-Related Osteonecrosis of the Jaw (MRONJ) in a Rat Model.
Brierly GI; Ren J; Baldwin J; Saifzadeh S; Theodoropoulos C; Tsurkan MV; Lynham A; Hsu E; Nikolarakos D; Werner C; Woodruff MA; Hutmacher DW; Bray LJ
Macromol Biosci; 2019 Nov; 19(11):e1900226. PubMed ID: 31549786
[TBL] [Abstract][Full Text] [Related]
64. Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy.
Kastritis E; Melea P; Bagratuni T; Melakopoulos I; Gavriatopoulou M; Roussou M; Migkou M; Eleutherakis-Papaiakovou E; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2017 Oct; 58(10):2304-2309. PubMed ID: 28604257
[TBL] [Abstract][Full Text] [Related]
65. Preventive dental management of osteonecrosis of the jaws related to zoledronic acid treatment.
Coello-Suanzes JA; Rollon-Ugalde V; Castaño-Seiquer A; Lledo-Villar E; Herce-Lopez J; Infante-Cossio P; Rollon-Mayordomo A
Oral Dis; 2018 Sep; 24(6):1029-1036. PubMed ID: 29412504
[TBL] [Abstract][Full Text] [Related]
66. Selective Percutaneous Controlled Radiofrequency Thermocoagulation of the Gasserian Ganglion To Control Facial Pain Due to Medication-Related Osteonecrosis of the Jaw.
Taniguchi A; Fukazawa K; Hosokawa T
J Palliat Med; 2017 Oct; 20(10):1171-1174. PubMed ID: 28772087
[TBL] [Abstract][Full Text] [Related]
67. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
Brown JJ; Ramalingam L; Zacharin MR
Clin Endocrinol (Oxf); 2008 Jun; 68(6):863-7. PubMed ID: 18221397
[TBL] [Abstract][Full Text] [Related]
68. Preventive Effect of Phosphodiesterase Inhibitor Pentoxifylline Against Medication-Related Osteonecrosis of the Jaw: An Animal Study.
Yalcin-Ulker GM; Cumbul A; Duygu-Capar G; Uslu Ü; Sencift K
J Oral Maxillofac Surg; 2017 Nov; 75(11):2354-2368. PubMed ID: 28529150
[TBL] [Abstract][Full Text] [Related]
69. Cytoprotective effects of melatonin on zoledronic acid-treated human mesenchymal stem cells in vitro.
Rodríguez-Lozano FJ; García-Bernal D; Ros-Roca Mde L; Algueró Mdel C; Oñate-Sánchez RE; Camacho-Alonso F; Moraleda JM
J Craniomaxillofac Surg; 2015 Jul; 43(6):855-62. PubMed ID: 26026888
[TBL] [Abstract][Full Text] [Related]
70. Response of a co-culture model of epithelial cells and gingival fibroblasts to zoledronic acid.
Basso FG; Soares DG; Pansani TN; Turrioni AP; Scheffel DL; Hebling J; Costa CA
Braz Oral Res; 2016 Nov; 30(1):e122. PubMed ID: 27901204
[TBL] [Abstract][Full Text] [Related]
71. Geranylgeraniol (GGOH) as a Mevalonate Pathway Activator in the Rescue of Bone Cells Treated with Zoledronic Acid: An In Vitro Study.
Fliefel RM; Entekhabi SA; Ehrenfeld M; Otto S
Stem Cells Int; 2019; 2019():4351327. PubMed ID: 30728841
[TBL] [Abstract][Full Text] [Related]
72. Sarcoglycans and integrins in bisphosphonate treatment: immunohistochemical and scanning electron microscopy study.
De Ponte FS; Favaloro A; Siniscalchi EN; Centofanti A; Runci M; Cutroneo G; Catalfamo L
Oncol Rep; 2013 Dec; 30(6):2639-46. PubMed ID: 24100935
[TBL] [Abstract][Full Text] [Related]
73. Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function.
Elsayed R; Abraham P; Awad ME; Kurago Z; Baladhandayutham B; Whitford GM; Pashley DH; McKenna CE; Elsalanty ME
Bone; 2018 May; 110():141-149. PubMed ID: 29408511
[TBL] [Abstract][Full Text] [Related]
74. Matrix-Bound Zolzoledronate Enhances the Biofilm Colonization of Hydroxyapatite: Effects on Osteonecrosis.
Elsayed R; El-Awady A; Cutler C; Kurago Z; Elashiry M; Sun C; Bloomquist R; Meghil MM; Elsalanty ME
Antibiotics (Basel); 2021 Nov; 10(11):. PubMed ID: 34827318
[TBL] [Abstract][Full Text] [Related]
75. The starting point for bisphosphonate-related osteonecrosis of the jaw: Alveolar bone or oral mucosa? A randomized, controlled experimental study.
Zandi M; Dehghan A; Janbaz P; Malekzadeh H; Amini P
J Craniomaxillofac Surg; 2017 Jan; 45(1):157-161. PubMed ID: 27919595
[TBL] [Abstract][Full Text] [Related]
76. Medication-Related Osteonecrosis of the Jaws Initiated by Zoledronic Acid and Potential Pathophysiology.
Alsalih A; Dam A; Lindberg P; Truedsson A
Dent J (Basel); 2021 Jul; 9(8):. PubMed ID: 34435997
[TBL] [Abstract][Full Text] [Related]
77. Standardized
Wiziack Zago PM; Oliveira Sousa IM; Servat-Medina L; Jorge MP; Lima Neto LG; Hass V; Li X; Tasca Gois Ruiz AL; Saxena D; Foglio MA
Clin Cosmet Investig Dent; 2020; 12():327-333. PubMed ID: 32848479
[TBL] [Abstract][Full Text] [Related]
78. Dual-Functional Drug Delivery System for Bisphosphonate-Related Osteonecrosis Prevention and Its Bioinspired Releasing Model and In Vitro Assessment.
Sungkhaphan P; Thavornyutikarn B; Muangsanit P; Kaewkong P; Kitpakornsanti S; Pornsuwan S; Singhatanadgit W; Janvikul W
ACS Omega; 2023 Jul; 8(29):26561-26576. PubMed ID: 37521598
[TBL] [Abstract][Full Text] [Related]
79. Overview on Adjunct Ingredients Used in Hydroxyapatite-Based Oral Care Products.
Enax J; Amaechi BT; Schulze Zur Wiesche E; Meyer F
Biomimetics (Basel); 2022 Dec; 7(4):. PubMed ID: 36546950
[TBL] [Abstract][Full Text] [Related]
80. The Effects of Various Food Products on Bisphosphonate's Availability.
Zielińska M; Garbacz G; Sczodrok J; Voelkel A
Pharmaceutics; 2022 Mar; 14(4):. PubMed ID: 35456551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
